相似文献
1
Small-molecule SMAC mimetics as new cancer therapeutics.
Pharmacol Ther. 2014 Oct;144(1):82-95. doi: 10.1016/j.pharmthera.2014.05.007. Epub 2014 May 16.
2
Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells.
ACS Chem Biol. 2014 Apr 18;9(4):994-1002. doi: 10.1021/cb400889a. Epub 2014 Feb 12.
3
SMAC Mimetics Induce Autophagy-Dependent Apoptosis of HIV-1-Infected Resting Memory CD4+ T Cells.
Cell Host Microbe. 2018 Nov 14;24(5):689-702.e7. doi: 10.1016/j.chom.2018.09.007. Epub 2018 Oct 18.
4
Characterization of Potent SMAC Mimetics that Sensitize Cancer Cells to TNF Family-Induced Apoptosis.
PLoS One. 2016 Sep 12;11(9):e0161952. doi: 10.1371/journal.pone.0161952. eCollection 2016.
5
Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma.
Mol Cancer Ther. 2013 Sep;12(9):1728-37. doi: 10.1158/1535-7163.MCT-13-0017. Epub 2013 May 22.
6
Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2.
Biochem Biophys Res Commun. 2009 Jan 9;378(2):162-7. doi: 10.1016/j.bbrc.2008.10.139. Epub 2008 Nov 4.
7
Design of small-molecule Smac mimetics as IAP antagonists.
Curr Top Microbiol Immunol. 2011;348:89-113. doi: 10.1007/82_2010_111.
8
Structure-based design and molecular profiling of Smac-mimetics selective for cellular IAPs.
FEBS J. 2018 Sep;285(17):3286-3298. doi: 10.1111/febs.14616. Epub 2018 Aug 16.
9
Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2.
Cell Death Differ. 2011 Aug;18(8):1376-86. doi: 10.1038/cdd.2011.10. Epub 2011 Feb 18.
10
Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression.
Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11936-41. doi: 10.1073/pnas.1005667107. Epub 2010 Jun 14.
引用本文的文献
1
Computational and experimental discovery of peptide inhibitors targeting survivin for therapeutic potential in cancer.
Sci Rep. 2025 Aug 20;15(1):30599. doi: 10.1038/s41598-025-13110-3.
2
Multidrug Resistance: Are We Still Afraid of the Big Bad Wolf.
Pharmaceuticals (Basel). 2025 Jun 14;18(6):895. doi: 10.3390/ph18060895.
3
Global siRNA screen identifies human host factors critical for SARS-CoV-2 replication and late stages of infection.
PLoS Biol. 2025 Jun 12;23(6):e3002738. doi: 10.1371/journal.pbio.3002738. eCollection 2025 Jun.
4
Macrophage regulated cell death: implications and mechanisms in organ transplantation.
Front Immunol. 2025 May 23;16:1604429. doi: 10.3389/fimmu.2025.1604429. eCollection 2025.
5
Circulating Tumour DNA in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer and Early Disease Progression After First-Line Osimertinib Treatment: The ELUCIDATOR Multicentre Prospective Observational Study.
Cancer Med. 2025 Apr;14(7):e70861. doi: 10.1002/cam4.70861.
6
Parthanatos and apoptosis: unraveling their roles in cancer cell death and therapy resistance.
EXCLI J. 2025 Mar 4;24:351-380. doi: 10.17179/excli2025-8251. eCollection 2025.
7
Synergistic Activity of Second Mitochondrial-Derived Activator of Caspases Mimetic with Toll-like Receptor 8 Agonist Reverses HIV-1-Latency and Enhances Antiviral Immunity.
Int J Mol Sci. 2025 Mar 13;26(6):2575. doi: 10.3390/ijms26062575.
8
A Perspective on Therapeutic Targeting Against Ubiquitin Ligases to Stabilize Tumor Suppressor Proteins.
Cancers (Basel). 2025 Feb 13;17(4):626. doi: 10.3390/cancers17040626.
9
Targeting cIAP2 in a novel senolytic strategy prevents glioblastoma recurrence after radiotherapy.
EMBO Mol Med. 2025 Apr;17(4):645-678. doi: 10.1038/s44321-025-00201-x. Epub 2025 Feb 19.
10
High-throughput drug screening identifies SMAC mimetics as enhancers of NK-cell cytotoxicity in chronic myeloid leukemia.
Blood. 2025 Apr 10;145(15):1670-1686. doi: 10.1182/blood.2024025286.
本文引用的文献
1
Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
Mol Cancer Ther. 2014 Apr;13(4):867-79. doi: 10.1158/1535-7163.MCT-13-0798. Epub 2014 Feb 21.
2
Identification of DR5 as a critical, NF-κB-regulated mediator of Smac-induced apoptosis.
Cell Death Dis. 2013 Nov 28;4(11):e936. doi: 10.1038/cddis.2013.457.
3
Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity.
Cell Death Dis. 2013 Nov 14;4(11):e920. doi: 10.1038/cddis.2013.449.
4
Targeting apoptosis pathways for new cancer therapeutics.
Annu Rev Med. 2014;65:139-55. doi: 10.1146/annurev-med-010713-141310. Epub 2013 Nov 4.
5
IAP proteins as targets for drug development in oncology.
Onco Targets Ther. 2013 Sep 16;9:1285-304. doi: 10.2147/OTT.S33375.
6
Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist.
Drug Metab Dispos. 2013 Dec;41(12):2104-13. doi: 10.1124/dmd.113.053926. Epub 2013 Sep 16.
7
IAPs on the move: role of inhibitors of apoptosis proteins in cell migration.
Cell Death Dis. 2013 Sep 5;4(9):e784. doi: 10.1038/cddis.2013.311.
8
Signaling networks of Rho GTPases in cell motility.
Cell Signal. 2013 Oct;25(10):1955-61. doi: 10.1016/j.cellsig.2013.04.009. Epub 2013 May 11.
9
The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.
Clin Cancer Res. 2013 Apr 1;19(7):1784-94. doi: 10.1158/1078-0432.CCR-12-2518. Epub 2013 Feb 12.
10
Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation.
Cancer Discov. 2013 Feb;3(2):212-23. doi: 10.1158/2159-8290.CD-12-0271. Epub 2012 Dec 26.
Zotero 插件